+3.35% for Amgen stock as Gilpin, ING Groep NV, Motley Fool increase holdings

Traders Union
All News
Financial News
Amgen jumps 3.35% to $349.04 today

Highlights

Significant institutional accumulation, including new positions from Gilpin Wealth Management and ING Groep, signals rising demand for Amgen shares.
Amgen’s MARITIME phase III trial for obesity drug MariTide, spanning nine global studies, fuels ongoing investor interest.
AMGN exhibits a bullish technical structure with strong buyer pressure, expected to trade in a $330.86–$357.47 range; upside probability is very high.

Institutional inflows and clinical progress drive renewed investor demand

Amgen is seeing notable institutional accumulation, as Gilpin Wealth Management LLC disclosed a new position in the company during the fourth quarter, while ING Groep NV reported the purchase of 2,988 Amgen shares and Motley Fool Asset Management LLC grew its stake by 35.9%, as recorded in regulatory filings. These inflows from significant asset managers suggest increased demand for Amgen shares and underline a broader institutional appetite, potentially helping to support the recent move higher. Meanwhile, Amgen continues to advance its clinical ambitions, progressing its MARITIME phase III program for the obesity drug candidate MariTide, with nine global studies in progress, driving fundamental investor interest.

Conflicting momentum signals emerge as price tests bullish range

On the hourly chart, AMGN is trading above the MA-20 at $344.50 and the MA-50 at $342.19, while on the daily chart, price remains above the MA-200 at $330.07. The Ichimoku Kijun sits at $347.05 and acts as immediate support. MACD and the Awesome Oscillator are both indicating a sell bias, and the ADX reading is neutral, highlighting weak momentum for the time being. The RSI is at 52.79 and signals a buy, while both the Stoch RSI and BBP are overbought, reflecting strong recent buyer activity. The CCI remains neutral, and the session's sharp $7.85 gap up with price near the top of today's range underscores ongoing bullish intraday sentiment despite conflicting momentum indicators.

High breakout odds persist as consolidation anchors the outlook

In the short term, AMGN is expected to remain within a volatility band of $330.86 to $357.47. The likelihood of an upward breakout is classified as very high, with limited downside risk within this band. The baseline scenario favors consolidation within this corridor, but a sustained close above resistance could trigger further gains. Conversely, a breach below immediate support near the Kijun or the range low may open a path for corrective downside movement.

Viktoras Karapetjanc, expert at Traders Union, sees robust institutional accumulation and strong clinical momentum fueling Amgen’s constructive setup. He notes recent buying by multiple large asset managers and progress in Amgen’s obesity drug pipeline as key supports for current sentiment. Technicals highlight bullish price action above major averages, despite some mixed momentum signals. He expects Amgen to trade within the $330.86–$357.47 range in the short term, with a high probability of an upside breakout. "Institutional flows and fundamental catalysts suggest Amgen is primed for further gains if resistance gives way."

Previously it was reported that Amgen shares were experiencing mixed momentum within a consolidation phase, with analysts highlighting the potential for a new directional move upon a break above resistance. The current combination of strong institutional inflows and continued clinical progress provides additional upside catalysts, making it essential for investors to monitor for a sustained close above the consolidation corridor as a signal for the next trend leg.

Source of Data: AMGN Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.